@entity1141 , growth hormone treatment and body proportion: comparison with other syndromic and non-syndromic short XXXX .

@entity1 @entity2338 @entity36519 @entity5884 @entity1141 @entity19008 @entity214
@entity1141 comprise a diverse group of conditions that usually compromise both linear growth and body proportions. It is of theoretical interest to evaluate the effect of @entity2338 treatment on linear growth, body proportion and final height in the different @entity1141 . Reported experience of @entity2338 treatment in short @entity1 with @entity1141 is sparse and often limited to short treatment periods and knowledge of its effects on final height and body proportion is generally lacking. Formal studies are almost all @entity5884 as the most common entity. First-year response is typically a 2-3 cm increase in growth velocity in prepubertal @entity1 , or a gain of about 0.5 @entity214 or less in relative height from a baseline level of -4 to -5 @entity214 . @entity2338 treatment for up to 5 years in achondroplasia can produce a total height gain of about 1 @entity214 . Apart from achondroplasia, treatment of @entity19008 and @entity36519 with @entity2338 has been reported in a small number of @entity1 . Long-term data are, however, lacking. Of theoretical interest is that in many syndromic or non-syndromic short-statured @entity1 body proportion, i.e. trunk to leg length ratio, does not seem to be dependent on the degree of @entity2338 sufficiency and does not seem to be changed by @entity2338 treatment. @entity2338 treatment, at least in the prepubertal period, does seem to influence degree of disproportion.
